The Amyloidosis Research Consortium was formed to help improve the understanding of the systemic amyloid diseases. The consortium brings together experts in the field to work as a team on cutting edge research. The ARC is developing a pipeline of key clinical trials and promising therapies.
This research organization is committed to building relationships among patients, academia, industry, foundations, government, and regulators in order to swiftly deliver new treatments to market. In partnership with the Amyloidosis Foundation, the Amyloidosis Research Consortium is driven by patient needs and dedicated to advocating on their behalf.